Country: Canada
Language: English
Source: Health Canada
DOXYCYCLINE (DOXYCYCLINE HYCLATE)
DEN-MAT HOLDINGS, LLC
A01AB22
DOXYCYCLINE
8.8%
GEL (CONTROLLED-RELEASE)
DOXYCYCLINE (DOXYCYCLINE HYCLATE) 8.8%
SUBGINGIVAL
250ML
Prescription
ANTIBACTERIALS
Active ingredient group (AIG) number: 0105569007; AHFS:
APPROVED
2000-07-05
PM-001 ATRIDOX ® _Product Monograph_ Page 1 of 27 ECR#27139 Rev Date: 23 June 2021 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ATRIDOX ® CONTROLLED-RELEASE DOXYCYCLINE GEL 8.8% w/w Doxycycline (as Hyclate) in DOXYGEL™ Delivery System Antimicrobial Agent for Periodontitis Manufactured by: Den-Mat Holdings, LLC Date of Initial Approval: 1017 W. Central Ave. July 5, 2000 Lompoc, CA 93436 U.S.A. Imported by: Date of Revision: Radiant Global Logistics June 28, 2021 3520 Laird Rd., unit 4 Mississauga, Ontario, Canada L5L 5Z7 Distributed by: Henry Schein 345 Townline Rd Niagara on the Lake, ON, L0S 1J0, CA Submission Control No: 242758 PM-001 ATRIDOX ® _Product Monograph_ Page 2 of 27 ECR#27139 Rev Date: 23 June 2021 RECENT MAJOR LABEL CHANGES Not Applicable TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATIONS................................................................................................................ 4 1.1 Pediatrics............................................................................................................ 4 1.2 Geriatrics ............................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.1 Dosing Considerations ........................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ..................................................... 5 4.3 Administration ..................................................................................................... 5 4.4 Reconstitution ....................................................................... Read the complete document